SCHEMBL6402273

SCHEMBL6402273

O=C(CCc1cccc(O)c1)c1ccc(O)cc1SP(=O)(O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP19A1 P11511 1/20 0.40
IDO1 P14902 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
DRD2 P14416 1/20 0.39
DRD1 P21728 1/20 0.39
TAAR1 Q96RJ0 1/20 0.39
AKR1B10 O60218 1/20 0.38
AKR1B1 P15121 1/20 0.38
MIF P14174 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
SLC5A1 P13866 1/20 0.37
SLC5A2 P31639 1/20 0.37
ANPEP P15144 1/20 0.37
ERAP2 Q6P179 1/20 0.37
ERAP1 Q9NZ08 1/20 0.37
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397680 0.93 HDAC6 (0.43) IDO1HDAC6DRD2DRD1TAAR1
SCHEMBL6395728 0.90 CYP19A1 (0.40) MEN1KMT2ACYP19A1IDO1HDAC6
SCHEMBL6396960 0.88 MEN1 (0.53) MEN1KMT2ACYP19A1AKR1B10AKR1B1
SCHEMBL6396964 0.87 HIF1A (0.44) MEN1KMT2AIDO1AKR1B10AKR1B1
SCHEMBL6398687 0.82 HDAC6 (0.43) IDO1HDAC6DRD2DRD1TAAR1
SCHEMBL6403657 0.82 SLC5A1 (0.53) MEN1KMT2ACYP19A1IDO1HDAC6
SCHEMBL6399712 0.81 SLC5A1 (0.48) MEN1KMT2ACYP19A1IDO1HDAC6
SCHEMBL6403791 0.81 MEN1 (0.45) MEN1KMT2ACYP19A1AKR1B10AKR1B1
SCHEMBL6402277 0.80 MEN1 (0.44) MEN1KMT2ACYP19A1IDO1HDAC6
SCHEMBL6397454 0.79 DRD2 (0.42) IDO1DRD2DRD1TAAR1MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MEN1 1773/4885KMT2A 4852/4885CYP19A1 2666/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 MEN1 2179/4885KMT2A 4828/4885CYP19A1 2807/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 MEN1 1773/4885KMT2A 4852/4885CYP19A1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.